CoronaryAtlas logo
CoronaryAtlas
Matrix metalloproteinase-9
Pathway / Fibrous-cap degradation & rupture

Matrix metalloproteinase-9

MMP9protein

MMP-9 degrades extracellular matrix in the atherosclerotic fibrous cap, promoting rupture and thrombotic exposure.

Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencehigh
RationaleAnchor molecule; fibrous-cap matrix degradation and plaque rupture.
Druggability
DruggableYes
Known drugs / candidates5
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000100985

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
76
A — assay feasibility
72
E — evidence strength
75
T1DI (composite)
25
Specificity differential (R−C)-9
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 3
2anemia / acute blood lossmag 3
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 2
7high-demand / peri-operative stressmag 2
Coverage: 7/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 23 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.028
Open Targets association (STEMI)

Literature evidence(39)